Genetic defects in the human glycome

The spectrum of all glycan structures — the glycome — is immense. In humans, its size is orders of magnitude greater than the number of proteins that are encoded by the genome, one percent of which encodes proteins that make, modify, localize or bind sugar chains, which are known as glycans. In the past decade, over 30 genetic diseases have been identified that alter glycan synthesis and structure, and ultimately the function of nearly all organ systems. Many of the causal mutations affect key biosynthetic enzymes, but more recent discoveries point to defects in chaperones and Golgi-trafficking complexes that impair several glycosylation pathways. As more glycosylation disorders and patients with these disorders are identified, the functions of the glycome are starting to be revealed.

[1]  D. Gilbert,et al.  An updated review of the long-term neurological effects of galactosemia. , 2005, Pediatric neurology.

[2]  Munhyang Lee,et al.  Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. , 2003, Human molecular genetics.

[3]  J. Hancock GPI-anchor synthesis: Ras takes charge. , 2004, Developmental cell.

[4]  R. Wevers,et al.  Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder , 2005, Journal of Inherited Metabolic Disease.

[5]  Rita Gerardy-Schahn,et al.  The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter , 2001, Nature Genetics.

[6]  A Etzioni,et al.  Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. , 1992, The New England journal of medicine.

[7]  B. Hagberg,et al.  Carbohydrate-deficient glycoprotein syndromes: peculiar group of new disorders. , 1993, Pediatric neurology.

[8]  Ron A Wevers,et al.  Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. , 2006, Clinical chemistry.

[9]  Amos Etzioni,et al.  Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency , 2001, Nature Genetics.

[10]  Carolyn R. Bertozzi,et al.  Essentials of Glycobiology , 1999 .

[11]  M. Krieger,et al.  Retrograde transport on the COG railway. , 2006, Trends in cell biology.

[12]  K. Petry,et al.  Altered Follicle Stimulating Hormone Isoforms in Female Galactosaemia Patients , 1997, European Journal of Pediatrics.

[13]  H. Freeze,et al.  Correction of leukocyte adhesion deficiency type II with oral fucose. , 1999, Blood.

[14]  A. Helenius,et al.  Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: An updated nomenclature for CDG , 1999, Glycoconjugate Journal.

[15]  D. Kelleher,et al.  An evolving view of the eukaryotic oligosaccharyltransferase. , 2006, Glycobiology.

[16]  R. Proia,et al.  Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Denecke,et al.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies , 2003, European Journal of Pediatrics.

[18]  M. Huynen,et al.  POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome , 2005, Journal of Medical Genetics.

[19]  A. Shestakova,et al.  COG Complex‐Mediated Recycling of Golgi Glycosyltransferases is Essential for Normal Protein Glycosylation , 2006, Traffic.

[20]  R. Campbell,et al.  Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis. , 2001, Glycobiology.

[21]  K. Campbell,et al.  Molecular Recognition by LARGE Is Essential for Expression of Functional Dystroglycan , 2004, Cell.

[22]  K. Hoyte,et al.  Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Elsas,et al.  GALT deficiency causes UDP-hexose deficit in human galactosemic cells. , 2003, Glycobiology.

[24]  H. Freeze,et al.  Cryptogenic Liver Disease in Four Children: A Novel Congenital Disorder of Glycosylation , 2006, Pediatric Research.

[25]  R. Wevers,et al.  Patients with unsolved congenital disorders of glycosylation type II can be subdivided in six distinct biochemical groups. , 2005, Glycobiology.

[26]  D. Dykxhoorn,et al.  Genetic Analysis of the Subunit Organization and Function of the Conserved Oligomeric Golgi (COG) Complex , 2005, Journal of Biological Chemistry.

[27]  G. Matthijs,et al.  Carbohydrate deficient glycoprotein (CDG) syndrome type I. , 1997, Journal of medical genetics.

[28]  G. Matthijs,et al.  Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia). , 1999, Molecular genetics and metabolism.

[29]  M. Schwartz,et al.  Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli , 1999, European Journal of Human Genetics.

[30]  G. Matthijs,et al.  Effect of mutations found in carbohydrate‐deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2 , 1999, FEBS letters.

[31]  J. Dennis,et al.  Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation , 2001, Nature.

[32]  H. Freeze Update and perspectives on congenital disorders of glycosylation. , 2001, Glycobiology.

[33]  R. U. Margolis,et al.  Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Schwartz,et al.  Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia) , 2000, European Journal of Human Genetics.

[35]  S. Kornfeld,et al.  Assembly of asparagine-linked oligosaccharides. , 1985, Annual review of biochemistry.

[36]  W. Canfield,et al.  Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha / beta -subunits precursor gene. , 2006, American journal of human genetics.

[37]  Larry J. Smith Paroxysmal Nocturnal Hemoglobinuria , 2004, American Society for Clinical Laboratory Science.

[38]  H. Brunner,et al.  Glyc‐O‐genetics of Walker–Warburg syndrome , 2004, Clinical genetics.

[39]  K. Campbell,et al.  LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies , 2004, Nature Medicine.

[40]  J. Lowe,et al.  Fucose: biosynthesis and biological function in mammals. , 2003, Glycobiology.

[41]  F. Muntoni Journey into muscular dystrophies caused by abnormal glycosylation. , 2004, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[42]  Susan C. Brown,et al.  Defective glycosylation in congenital muscular dystrophies , 2004, Current opinion in neurology.

[43]  P. Dawson,et al.  Pathogenetics of the human SLC26 transporters. , 2005, Current medicinal chemistry.

[44]  M. Betenbaugh,et al.  Controlling N-linked glycan site occupancy. , 2005, Biochimica et biophysica acta.

[45]  Wenli Zhang,et al.  The role of defective glycosylation in congenital muscular dystrophy , 2003, Glycoconjugate Journal.

[46]  W. Young Organization of Golgi Glycosyltransferases in Membranes: Complexity via Complexes , 2004, The Journal of Membrane Biology.

[47]  W. Lennarz,et al.  The molecular basis of coupling of translocation and N-glycosylation. , 2006, Trends in biochemical sciences.

[48]  R. Dwek,et al.  Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase , 2004, Nature Genetics.

[49]  J. Mcgill,et al.  Congenital disorder of glycosylation type Ia in a 6-year-old girl with a mild intellectual phenotype: Two novel PMM2 mutations , 2005, Journal of Inherited Metabolic Disease.

[50]  R. U. Margolis,et al.  High prevalence of 2-mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain glycopeptides by reductive alkaline hydrolysis. , 1999, European journal of biochemistry.

[51]  G. Matthijs,et al.  Annals of the New York Academy of Sciences Congenital Disorders of Glycosylation , 2022 .

[52]  H. Freeze,et al.  Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. , 1998, The Journal of clinical investigation.

[53]  K. Hwa Glycosyl phosphatidylinositol-linked glycoconjugates: structure, biosynthesis and function. , 2001, Advances in experimental medicine and biology.

[54]  N. Callewaert,et al.  Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[55]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[56]  Gerhard K. H. Przemeck,et al.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Guillaume Vogt,et al.  Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations , 2005, Nature Genetics.

[58]  J. Dennis,et al.  N-Acetylglucosaminyltransferase V (Mgat5)-Mediated N-Glycosylation Negatively Regulates Th1 Cytokine Production by T Cells1 , 2004, The Journal of Immunology.

[59]  Z. Werb,et al.  Mice deficient in Ext2 lack heparan sulfate and develop exostoses , 2005, Development.

[60]  J. Marth,et al.  Alpha-Mannosidase-II Deficiency Results in Dyserythropoiesis and Unveils an Alternate Pathway in Oligosaccharide Biosynthesis , 1997, Cell.

[61]  R. Spiro Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. , 2002, Glycobiology.

[62]  E. Mercuri,et al.  Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. , 2006, Archives of neurology.

[63]  V. Lemmon,et al.  A genetic model for muscle–eye–brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1) , 2006, Mechanisms of Development.

[64]  M. Mizuno,et al.  Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. , 2001, Developmental cell.

[65]  F. Muntoni,et al.  The congenital muscular dystrophies in 2004: a century of exciting progress , 2004, Neuromuscular Disorders.

[66]  R. Oriol,et al.  Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. , 2005, Blood.

[67]  M. Götte,et al.  Defective Glycosaminoglycan Substitution of Decorin in a Patient With Progeroid Syndrome Is a Direct Consequence of Two Point Mutations in the Galactosyltransferase I (ß4galT-7) Gene , 2005, Biochemical Genetics.

[68]  Mitsue Sano,et al.  The conserved oligomeric Golgi complex acts in organ morphogenesis via glycosylation of an ADAM protease in C. elegans , 2005, Development.

[69]  B. Henrissat,et al.  Mucolipidosis II is caused by mutations in GNPTA encoding the α/β GlcNAc-1-phosphotransferase , 2005, Nature Medicine.

[70]  K. Venkatachalam Human 3'‐phosphoadenosine 5'‐phosphosulfate (PAPS) Synthase: Biochemistry, Molecular Biology and Genetic Deficiency , 2003, IUBMB life.

[71]  R. Cummings,et al.  Protein glycosylation: Chaperone mutation in Tn syndrome , 2005, Nature.

[72]  H. Freeze,et al.  Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia , 2001, Genetics in Medicine.

[73]  W. Welch,et al.  Role of quality control pathways in human diseases involving protein misfolding. , 2004, Seminars in cell & developmental biology.

[74]  E. Schaftingen,et al.  Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia , 2003, Journal of Inherited Metabolic Disease.

[75]  N. Leslie Insights into the pathogenesis of galactosemia. , 2003, Annual review of nutrition.

[76]  M. Matzuk,et al.  Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. , 2000, Developmental biology.

[77]  R. Proia Gangliosides help stabilize the brain , 2004, Nature Genetics.

[78]  J. Marth,et al.  Dietary and Genetic Control of Glucose Transporter 2 Glycosylation Promotes Insulin Secretion in Suppressing Diabetes , 2005, Cell.

[79]  S. Fukumoto Post‐translational Modification of Fibroblast Growth Factor 23 , 2005, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[80]  H. Freeze,et al.  Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism☆☆☆ , 1999, The Journal of Pediatrics.

[81]  François Stricher,et al.  SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs , 2004, Nucleic Acids Res..

[82]  S. Kornfeld,et al.  COG-7-deficient Human Fibroblasts Exhibit Altered Recycling of Golgi Proteins. , 2006, Molecular biology of the cell.

[83]  S. Kornfeld,et al.  Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.

[84]  R. Senger,et al.  Variable Site‐Occupancy Classification of N‐Linked Glycosylation Using Artificial Neural Networks , 2005, Biotechnology progress.

[85]  Markus Aebi,et al.  Altered glycan structures: the molecular basis of congenital disorders of glycosylation. , 2005, Current opinion in structural biology.

[86]  M. Sacher Membrane traffic fuses with cartilage development , 2003, FEBS letters.

[87]  T. Nilsson,et al.  Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum. , 2003, Molecular biology of the cell.

[88]  J. Denecke,et al.  Congenital Disorder of Glycosylation Type Id: Clinical Phenotype, Molecular Analysis, Prenatal Diagnosis, and Glycosylation of Fetal Proteins , 2005, Pediatric Research.

[89]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[90]  S. Selleck,et al.  Order out of chaos: assembly of ligand binding sites in heparan sulfate. , 2002, Annual review of biochemistry.

[91]  P. Orlik,et al.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.

[92]  E. Engvall,et al.  The new frontier in muscular dystrophy research: booster genes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  P. Nowell Phytohemagglutinin: an initiator of mitosis in cultures of normal human leukocytes. , 1960, Cancer research.

[94]  J. Esko,et al.  Hereditary multiple exostoses and heparan sulfate polymerization. , 2002, Biochimica et biophysica acta.

[95]  M. Zaffanello,et al.  Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. , 2005, Glycobiology.

[96]  M. Raghunath,et al.  Truncated profibrillin of a Marfan patient is of apparent similar size as fibrillin: intracellular retention leads to over-N-glycosylation. , 1995, Journal of molecular biology.

[97]  H. Freeze,et al.  Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. , 2000, The American journal of pathology.

[98]  J. Paulson,et al.  Human Disease Glycomics/Proteome Initiative Workshop and the 4th HUPO Annual Congress , 2006, Proteomics.

[99]  H. Mitsuya,et al.  Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP. , 2006, Blood.

[100]  E. Berger,et al.  Deficiency of UDP-galactose:N-acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId. , 2002, The Journal of clinical investigation.

[101]  L. Peltonen,et al.  A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. , 1996, Genomics.

[102]  R. Wevers,et al.  Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis. , 2003, Clinical chemistry.

[103]  S. Hakomori Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization , 2004, Glycoconjugate Journal.

[104]  M. Hultén Chiasma distribution at diakinesis in the normal human male. , 2009, Hereditas.

[105]  R. Wevers,et al.  Defective protein glycosylation in patients with cutis laxa syndrome , 2005, European Journal of Human Genetics.

[106]  J. Paulson,et al.  Glycomics: an integrated systems approach to structure-function relationships of glycans , 2005, Nature Methods.

[107]  A. Nishikawa,et al.  The efficiency of N-linked glycosylation of bovine DNase I depends on the Asn-Xaa-Ser/Thr sequence and the tissue of origin. , 2001, The Biochemical journal.

[108]  J. Rowley A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[109]  H. Harris,et al.  Hybrid Cells Derived from Mouse and Man : Artificial Heterokaryons of Mammalian Cells from Different Species , 1965, Nature.

[110]  A. Tárnok,et al.  Correction: Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? , 2003, Critical care.

[111]  N. Debili,et al.  Macrothrombocytopenia with abnormal demarcation membranes in megakaryocytes and neutropenia with a complete lack of sialyl-Lewis-X antigen in leukocytes--a new syndrome? , 2001, Blood.

[112]  O. Bohorov,et al.  Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder , 2004, Nature Medicine.

[113]  E. Schaftingen,et al.  High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). , 2001, American journal of human genetics.

[114]  J. Jaeken,et al.  Congenital disorders of glycosylation (CDG): It's all in it! , 2003, Journal of Inherited Metabolic Disease.

[115]  P. Kwok,et al.  Identification of a frequent variant in ALG6, the cause of Congenital Disorder of Glycosylation‐Ic , 2003, Human mutation.

[116]  P. de Cock,et al.  Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II. , 1994, Archives of disease in childhood.

[117]  Lawrence A Tabak,et al.  All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. , 2003, Glycobiology.

[118]  H. Freeze,et al.  Applied glycoproteomics--approaches to study genetic-environmental collisions causing protein-losing enteropathy. , 2006, Biochimica et biophysica acta.

[119]  J. Jaeken,et al.  Congenital disorders of glycosylation: a booming chapter of pediatrics. , 2004, Current opinion in pediatrics.

[120]  M. Fukuda HEMPAS. Hereditary erythroblastic multinuclearity with positive acidified serum lysis test. , 1999, Biochimica et Biophysica Acta.

[121]  H. Freeze,et al.  Glycobiology of neuromuscular disorders. , 2003, Glycobiology.

[122]  J. Jaeken,et al.  Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, an autosomal recessive disease with defective brain development. , 1996, American journal of human genetics.